Privately held Anima Biotech Inc., a New Jersey-based small-molecule discovery platform company, has reached a multiyear deal with Eli Lilly and Co. to develop translation inhibitors for undisclosed target proteins of Lilly's choosing. Anima, formerly based in Tel Aviv, Israel, gains $30 million up front and $14 million in research funding under the terms of the agreement. It could receive up to $1.05 billion by achieving future development and commercial milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.